BTIG Research Reaffirms Buy Rating for Innate Pharma (NASDAQ:IPHA)

Innate Pharma (NASDAQ:IPHA)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research note issued on Thursday,Benzinga reports. They currently have a $8.00 price target on the stock. BTIG Research’s price target would indicate a potential upside of 416.13% from the company’s previous close.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Innate Pharma in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Innate Pharma Stock Performance

IPHA opened at $1.55 on Thursday. The business has a 50 day moving average price of $1.73 and a 200 day moving average price of $1.87. Innate Pharma has a twelve month low of $1.46 and a twelve month high of $2.63.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IPHA. Millennium Management LLC bought a new stake in shares of Innate Pharma in the fourth quarter valued at approximately $36,000. OLD Mission Capital LLC bought a new position in Innate Pharma during the fourth quarter worth $50,000. Finally, Jane Street Group LLC acquired a new position in Innate Pharma during the 4th quarter valued at $162,000. 0.16% of the stock is currently owned by institutional investors and hedge funds.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.